ATLANTA (July 2, 2015) – Rimidi has been selected as one of Five Georgia-Based Healthcare Startups to Watch For by the Georgia Pharmacy Association.
As part of the selection, Dr. Lucienne Ide, Rimidi CEO, will take part in a “Shark Tank-like” panel with four other healthcare startups on Sat., July 11 at the Georgia Pharmacy Convention 2015 in Amelia Island.
“We’re delighted to be selected as one of five Georgia healthcare companies to watch,” said Dr. Ide. “Our technology, Diabetes+Me™, is being used by pharmacists to help provide care, increase patient engagement and reduce costs. I’m looking forward to sharing our latest data and receiving feedback.”
Phillip Ratliff, GPhA’s VP of Communication and Engagement, said, “We’re excited to have selected Dr. Ide for the Five Georgia Startups to Watch For panel. Dr. Ide and her Diabetes+Me program epitomize the sort of forward-looking, entrepreneurial spirit we’re all about at the Georgia Pharmacy Association. It’s an honor to have her join our fantastic line-up of selected presenters.”
Diabetes+Me™ provides a cloud-based platform for diabetes management. Through its software platform, patients can track their health and lifestyle data, as well as obtain medical and nutritional information about their condition. Healthcare providers can leverage the data through proprietary analytics that drive targeted decision-making for treatment options, population management and improved care.
Diabetes+Me is currently being piloted by Desert Oasis Healthcare (DOHC) in Palm Springs, Calif., an affiliated medical group of the Heritage Provider Network (HPN) and Heritage ACO. The Medication Management Department is conducting a study of two groups: one treated with the standard of care with the pharmacist and the other treated with the standard of care with the pharmacist combined with the Rimidi app.
The goal of the study is to test the software’s ability to lower A1C levels, improve patient engagement and enhance the clinic’s efficiency in providing quality diabetes care. It also will study whether the technology helps the pharmacist’s decision-making in adjusting medications according to a patient’s individual needs. Initial results have found that using the Diabetes+Me app combined with the pharmacist’s care reduces A1C levels by more than 2 percent and increases patient satisfaction compared to the group that didn’t receive the app, according to DOHC.
Earlier this year, Rimidi announced an investment from Cox Enterprises to expand its efforts into other markets, including retail pharmacies, medical clinics and employee wellness.
Rimidi is an Atlanta-based, woman-led digital health company bringing to market data analytics and disease management solutions. Its flagship product, Diabetes+Me™, is a software solution focused on empowering quality diabetes care for healthcare organizations and providers. Rimidi has received funding from SOURCE, a partnership between the Hitachi Foundation, Investor’s Circle and Village Capital. The company also received funding from the JumpFund, whose mission is to invest women’s capital in female-led companies with growth potential. For more information, visit www.rimidi.com.